Case Report
Accepted on 29 Sep 2025
Case Report: Fluzoparib Combined Exemestane in gBRCA2-mutated HR+/HER2− Advanced Breast Cancer
in Pharmacology of Anti-Cancer Drugs
Case Report
Accepted on 29 Sep 2025
in Pharmacology of Anti-Cancer Drugs
Original Research
Accepted on 29 Sep 2025
in Vaccines and Molecular Therapeutics
Case Report
Accepted on 29 Sep 2025
in Surgical Oncology
Original Research
Accepted on 29 Sep 2025
in Veterinary Pharmacology and Toxicology
Opinion
Accepted on 29 Sep 2025
in Veterinary Epidemiology and Economics
Review
Accepted on 29 Sep 2025
in Environmental Degradation of Materials
Original Research
Accepted on 29 Sep 2025
in Controlled Environment Horticulture
Opinion
Accepted on 29 Sep 2025
in Climate and Economics
Original Research
Accepted on 29 Sep 2025
in Orthopedic Surgery
Original Research
Accepted on 29 Sep 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 29 Sep 2025
in Nutrition and Metabolism
Hypothesis and Theory
Accepted on 29 Sep 2025
in Cognition
Perspective
Accepted on 29 Sep 2025
in Antibiotic Resistance and New Antimicrobial drugs
Original Research
Accepted on 29 Sep 2025
in Animal Nutrition and Metabolism
Review
Accepted on 29 Sep 2025
in Ethnopharmacology
Original Research
Accepted on 29 Sep 2025
in Georeservoirs